Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Bevacizumab Biosimilar, and PLD in Pretreated Metastatic TNBC
NCT05386524Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoints: Progression-Free Survival at 6 weeks, Overall Survival at 6 weeks and 1 more. Status: unknown.
02
Drugs
sintilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05386524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386524.